COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03889483
Previous Study | Return to List | Next Study

Neurophysiological Measurements Using the NeuroCatch™ Platform in Pediatric Concussion

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03889483
Recruitment Status : Recruiting
First Posted : March 26, 2019
Last Update Posted : January 13, 2021
Sponsor:
Collaborator:
NeuroCatch Inc.
Information provided by (Responsible Party):
Dr. Michael Esser, Alberta Children's Hospital

Tracking Information
First Submitted Date  ICMJE March 22, 2019
First Posted Date  ICMJE March 26, 2019
Last Update Posted Date January 13, 2021
Actual Study Start Date  ICMJE November 30, 2018
Estimated Primary Completion Date September 30, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 22, 2019)
  • Tracking and comparison of neurophysiological changes (ERP response size) to persistence of mTBI symptoms [ Time Frame: 1 day ]
    Response size will be measured as amplitude in microvolts. Persistence of mTBI symptoms will be defined by cohort.
  • Tracking and comparison of neurophysiological changes (ERP response timing) to persistence of mTBI symptoms [ Time Frame: 1 day ]
    Response timing will be measured as latency in milliseconds. Persistence of mTBI symptoms will be defined by cohort.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: March 25, 2019)
  • Number of adverse events and adverse device effects [ Time Frame: 1 day ]
    Assessing the safety and performance of the NeuroCatchTM Platform in four pediatric cohorts.
  • Collection of ERP response size (amplitude in microvolts) and response timing (latency in milliseconds) [ Time Frame: 1 day ]
    Quantifying the natural variability in selected ERPs (N100, P300, N400) acquired using the NeuroCatchTM Platform in one study session.
Original Secondary Outcome Measures  ICMJE
 (submitted: March 22, 2019)
  • Collection of adverse events and adverse device effects [ Time Frame: 1 day ]
    Assessing the safety and performance of the NeuroCatchTM Platform in four pediatric cohorts.
  • Collection of ERP response size (amplitude in microvolts) and response timing (latency in milliseconds) [ Time Frame: 1 day ]
    Quantifying the natural variability in selected ERPs (N100, P300, N400) acquired using the NeuroCatchTM Platform in one study session.
Current Other Pre-specified Outcome Measures
 (submitted: March 22, 2019)
Explore trends between select additional measures of impairment and ERPs across four pediatric cohorts. [ Time Frame: 1 day ]
Additional measures of impairment may include cognitive assessments, blood work and DNA analysis, brain imaging (MRI) and levels of carbon dioxide in the breath.
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE Neurophysiological Measurements Using the NeuroCatch™ Platform in Pediatric Concussion
Official Title  ICMJE Neurophysiological Measurements in the Pediatric Concussion Population: An Initial Assessment Using the NeuroCatch™ Platform
Brief Summary

EEG signals have been collected and studied since the early 1990's as a way of assessing brain function at a gross level. As early as the 1930's a derivative of the raw EEG signal - event-related potentials (ERPs) - have been computed. The current research is primarily focused on three ERP components: the N100, P300 and N400. Each of the three ERPs have been studied in the academic laboratory for multiple decades. Through this research, a strong understanding has been developed regarding what can affect these components (e.g. task set, emotional state, etc.). However, these signals within various pediatric populations (e.g., those with persistent mTBI symptoms or multiple concussions) are not well characterized.

Being able to safely and effectively employ the NeuroCatch™ Platform in a post-concussive pediatric cohort could provide researchers with the potential to elucidate the persistence of objective measures of impairment, patterns of recovery, and chronicity of problems due to mTBI in children. Secondly, understanding the degree to which these neurophysiological components fluctuate over time is crucial to the understanding of brain functioning. However, for this type of technology to be useful in quantifying brain health in this population,the degree to which a post-concussive pediatric brain naturally fluctuates in its processing capability must be quantified. NeuroCatch™ Platform has the ability to measure changes in several domains of brain function. These cognitive processes are foundational blocks for some of the highest cognitive processes: information integration and executive functioning.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:

Participants will be divided into the following cohorts:

Cohort 1: 30 participants with persistent mTBI symptoms (duration greater than 6 weeks), as determined by the Investigator; Cohort 2: 30 participants who recovered quickly from mTBI (i.e., within approximately six weeks based on symptomatology), as determined by the Investigator; Cohort 3: 15 participants who have had multiple mTBIs (2 or more medically verified concussions over the last year); and Cohort 4: 30 participants who have never had a concussion. Participants in Cohorts 1-3 will be recruited 6-16 weeks post injury date.

After study enrollment, all participants undergo two NeuroCatch Platform assessments.

Masking: None (Open Label)
Primary Purpose: Other
Condition  ICMJE
  • Children, Only
  • Traumatic Brain Injury
  • Concussion, Mild
  • Pediatric ALL
Intervention  ICMJE Device: NeuroCatch™ Platform
The NeuroCatch™ Platform consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
Study Arms  ICMJE NeuroCatch™ Platform Assessment
All participants will undergo two NeuroCatch™ Platform Assessments.
Intervention: Device: NeuroCatch™ Platform
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: March 22, 2019)
105
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 30, 2021
Estimated Primary Completion Date September 30, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Male, female, or intersex
  2. 8-18 years old inclusively
  3. Must meet all criteria in one of the following cohorts:

    1. Cohort 1: Has persistent mTBI symptoms 6-16 weeks post-injury, as determined by the Investigator;
    2. Cohort 2: Recovered quickly (within approximately six weeks) from mTBI, as determined by the Investigator 6-16 weeks post-injury;
    3. Cohort 3: Has had multiple mTBIs (2 or more medically verified concussions over the last year) with the most recent injury having occurred 6-16 weeks prior to study enrollment;
    4. Cohort 4: Has never had a concussion.

Exclusion Criteria:

  1. Previous neurological illnesses (e.g., epilepsy or seizure disorders) including moderate to severe learning difficulties, as determined by the Investigator
  2. Clinically documented hearing issues (e.g., tinnitus, in-ear hearing problems, punctured ear drum)
  3. In-ear hearing aid or cochlear implant, hearing devices
  4. Implanted pacemaker
  5. Metal or plastic implants in skull
  6. Allergy to rubbing alcohol or EEG gel
  7. Previous participation in one or more studies using the NeuroCatchTM Platform
  8. Unhealthy scalp (apparent open wounds and/or bruised or weakened skin)
  9. Using other investigational drugs or devices while enrolled in this study
  10. Not fluent in the English language
  11. If female and of child-bearing potential: suspected or planning to become pregnant, currently pregnant, or breast-feeding
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 8 Years to 18 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Michael Esser, MD (403) 955 -7911 Michael.Esser@albertahealthservices.ca
Listed Location Countries  ICMJE Canada
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03889483
Other Study ID Numbers  ICMJE ACH-NCI-001
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party Dr. Michael Esser, Alberta Children's Hospital
Study Sponsor  ICMJE Dr. Michael Esser
Collaborators  ICMJE NeuroCatch Inc.
Investigators  ICMJE
Principal Investigator: Michael Esser University of Calgary
PRS Account Alberta Children's Hospital
Verification Date January 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP